JP2021512109A5 - - Google Patents
Info
- Publication number
- JP2021512109A5 JP2021512109A5 JP2020541807A JP2020541807A JP2021512109A5 JP 2021512109 A5 JP2021512109 A5 JP 2021512109A5 JP 2020541807 A JP2020541807 A JP 2020541807A JP 2020541807 A JP2020541807 A JP 2020541807A JP 2021512109 A5 JP2021512109 A5 JP 2021512109A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- group
- optionally substituted
- substituents independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192455A JP2024019396A (ja) | 2018-01-31 | 2023-11-10 | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624218P | 2018-01-31 | 2018-01-31 | |
| US62/624,218 | 2018-01-31 | ||
| US201862718107P | 2018-08-13 | 2018-08-13 | |
| US62/718,107 | 2018-08-13 | ||
| PCT/US2019/016098 WO2019152678A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192455A Division JP2024019396A (ja) | 2018-01-31 | 2023-11-10 | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512109A JP2021512109A (ja) | 2021-05-13 |
| JP2021512109A5 true JP2021512109A5 (https=) | 2022-02-01 |
Family
ID=65494516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541807A Pending JP2021512109A (ja) | 2018-01-31 | 2019-01-31 | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
| JP2023192455A Withdrawn JP2024019396A (ja) | 2018-01-31 | 2023-11-10 | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192455A Withdrawn JP2024019396A (ja) | 2018-01-31 | 2023-11-10 | スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210047324A1 (https=) |
| EP (1) | EP3746442A1 (https=) |
| JP (2) | JP2021512109A (https=) |
| KR (1) | KR20200115610A (https=) |
| CN (1) | CN112218866A (https=) |
| AU (1) | AU2019215049A1 (https=) |
| BR (1) | BR112020015666A2 (https=) |
| CA (1) | CA3089559A1 (https=) |
| CL (1) | CL2020001990A1 (https=) |
| IL (1) | IL276330A (https=) |
| MX (1) | MX2020008106A (https=) |
| PE (1) | PE20211455A1 (https=) |
| PH (1) | PH12020551140A1 (https=) |
| SG (1) | SG11202007251XA (https=) |
| WO (1) | WO2019152678A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151416A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| KR102465758B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7036792B2 (ja) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2024354932A1 (en) * | 2023-10-03 | 2026-04-09 | Revolution Medicines, Inc. | Synthesis of ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) * | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
| CN102267995A (zh) * | 2010-06-04 | 2011-12-07 | 艾琪康医药科技（上海）有限公司 | 一种制备二氮杂螺环化合物的方法 |
| EP2951186B1 (en) * | 2013-01-29 | 2018-07-25 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9758525B2 (en) * | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| JP2016506962A (ja) * | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| KR102410989B1 (ko) * | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| PE20151416A1 (es) * | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| MX379622B (es) * | 2015-04-03 | 2025-03-11 | Recurium Ip Holdings Llc | Compuestos espirociclicos |
| WO2017201285A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190174A1 (es) * | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| KR102465758B1 (ko) * | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| AR110988A1 (es) * | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| JP2022092387A (ja) * | 2020-12-10 | 2022-06-22 | キヤノン株式会社 | 画像形成装置 |
-
2019
- 2019-01-31 PE PE2020001149A patent/PE20211455A1/es unknown
- 2019-01-31 AU AU2019215049A patent/AU2019215049A1/en not_active Abandoned
- 2019-01-31 KR KR1020207024903A patent/KR20200115610A/ko not_active Withdrawn
- 2019-01-31 US US16/966,176 patent/US20210047324A1/en not_active Abandoned
- 2019-01-31 BR BR112020015666-3A patent/BR112020015666A2/pt not_active Application Discontinuation
- 2019-01-31 MX MX2020008106A patent/MX2020008106A/es unknown
- 2019-01-31 CA CA3089559A patent/CA3089559A1/en active Pending
- 2019-01-31 CN CN201980018351.6A patent/CN112218866A/zh active Pending
- 2019-01-31 EP EP19706076.7A patent/EP3746442A1/en not_active Withdrawn
- 2019-01-31 WO PCT/US2019/016098 patent/WO2019152678A1/en not_active Ceased
- 2019-01-31 JP JP2020541807A patent/JP2021512109A/ja active Pending
- 2019-01-31 SG SG11202007251XA patent/SG11202007251XA/en unknown
-
2020
- 2020-07-27 IL IL276330A patent/IL276330A/en unknown
- 2020-07-28 PH PH12020551140A patent/PH12020551140A1/en unknown
- 2020-07-30 CL CL2020001990A patent/CL2020001990A1/es unknown
-
2023
- 2023-11-10 JP JP2023192455A patent/JP2024019396A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512109A5 (https=) | ||
| JP2021512098A5 (https=) | ||
| JP2024520481A5 (https=) | ||
| JP2016513130A5 (https=) | ||
| RU2018104278A (ru) | Оксистеролы и способы их применения | |
| HRP20241540T1 (hr) | Pirolotriazinski spojevi koji djeluju kao inhibitor mnk | |
| HRP20210926T1 (hr) | Derivati 1h-indazol-3-karboksamida i povezani spojevi kao inhibitori faktora d za liječenje bolesti karakteriziranih pojačanom djelatnošću sustava komplemenata, kao npr. imunološki poremećaji | |
| AR066904A1 (es) | Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer | |
| ME02875B (me) | Inhibitori hcv polimeraze | |
| JP2020504707A5 (https=) | ||
| JP2017531020A5 (https=) | ||
| RU2018115569A (ru) | Оксаспиропроизводное, способ его получения и его применения в лекарственных средствах | |
| JP2016503052A5 (https=) | ||
| JP2014051526A5 (https=) | ||
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| JP2010510237A5 (https=) | ||
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| IL276332B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| RU2019116512A (ru) | Ингибиторы magl | |
| JP2023533203A5 (https=) | ||
| RU2018145808A (ru) | Производное фенилпропанамида, способ его получения и его фармацевтическое применение | |
| JP2020502047A5 (https=) | ||
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| RU2008107733A (ru) | Ингибиторы gsk-3 |